Navigation Links
Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia

A new study is providing scientists with a better understanding of why some pediatric acute lymphoblastic leukemia (ALL) patients fail to respond to treatment even when existing clinical predictive criteria point towards a positive treatment outcome. The research, published in the April issue of Cancer Cell, is likely to facilitate development of new strategies to combat drug resistance and treatment failure for children with ALL.

Nearly 80% of children with ALL are cured following chemotherapeutic treatment. However, the remaining 20% often exhibit drug resistance and treatment failure that is poorly understood. In some cases, patients are resistant to multiple drugs that have very little structural similarity, suggesting that the mechanisms for drug cross-resistance are probably not the same as mechanisms underlying resistance to a single drug. Dr. William E. Evans from St. Jude Children's Research Hospital and colleagues used a comprehensive genetic screening technique to search for genes that are differentially expressed in ALL cells that demonstrated cross-resistance to two or more commonly used chemotherapeutic agents.

The researchers identified several genes that were differentially expressed in ALL cells that exhibited de novo cross resistance to four widely used antileukemic agents. They went on to investigate the relationship of these genes to treatment outcome in ALL patients and found that expression of the genes was associated with treatment outcome and could be used to identify a subset of patients with a markedly inferior response to treatment. In addition, the findings revealed a previously unrecognized phenotype characterized by discordant resistance to two widely used and mechanistically distinct antileukemic agents and provided new information about the cellular mechanisms involved in disparate response to these drugs.

Specific genetic signatures related to ALL treatment failure and chemotherapeutic cross-resistance were mor e effective at identifying select populations of patients with inferior treatment outcomes than expression patterns associated with resistance to a single drug. "These findings provide new insights into the biological basis of de novo multiple-drug resistance and illuminate potential new targets for overcoming this cause of treatment failure in childhood ALL," explains Dr. Evans.


'"/>

Source:Cell Press


Related biology news :

1. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
2. Drug-resistant bacteria on poultry products differ by brand
3. Genetic discovery could lead to drought-resistant plants
4. UF researchers kill resistant bugs one bandage at a time
5. DDT-resistant insects have additional genetic advantage that helps resistance spread
6. Drug resistant avian influenza viruses more common in Southeast Asia than North America
7. New molecule may aid in production of biofuels and fungi-resistant plants
8. Reducing antibiotic use lowers rates of drug-resistant bacteria
9. New class of antibiotics effective against drug-resistant bacteria discovered in fungi
10. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
11. Virginia Tech helping to develop higher quality, disease-resistant wheat varieties
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
(Date:3/15/2016)... Yissum Research Development Company of the Hebrew University ... University, announced today the formation of Neteera Technologies ... biological indicators. Neteera Technologies has completed its first round ... Neteera,s ... from sweat ducts, enables reliable and speedy biometric identification, ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, ... spinal surgical procedures, today announced the completion of a significant transaction and partnership ... and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading ...
(Date:4/29/2016)... ... April 29, 2016 , ... During a two day program ... viable company, CereScan’s CEO, John Kelley, joined other Denver business leaders in providing ... in the Denver area business community, shared his top fundamental learnings in building ...
(Date:4/29/2016)... ... 2016 , ... Intelligent Implant Systems announced today that the two-level components for ... the United States. These components expand the capabilities of the system and allow ... in October of 2015, the company has seen significant sales growth in 1Q 2016, ...
(Date:4/28/2016)... 2016 The report "Cryocooler Market ... Service (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, ... to 2022", published by MarketsandMarkets, the global market is ... at a CAGR of 7.29% between 2016 and 2022. ... 94 Figures spread through 159 Pages and in-depth TOC ...
Breaking Biology Technology: